Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma

BACKGROUND: There is no universally accepted treatment for patients with advanced papillary renal cell carcinoma (PRCC). The presence of activating mutations in MET, as well as gain of chromosome 7, where the MET gene is located, are the most common genetic alterations associated with PRCC, leading...

Descripción completa

Detalles Bibliográficos
Autores principales: Pahwa, Roma, Dubhashi, Janhavi, Singh, Anand, Jailwala, Parthav, Lobanov, Alexei, Thomas, Craig J., Ceribelli, Michele, Wilson, Kelli, Ricketts, Christopher J., Vocke, Cathy D., Wells, Catherine, Bottaro, Donald P., Linehan, W. Marston, Neckers, Len, Srinivasan, Ramaprasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235180/
https://www.ncbi.nlm.nih.gov/pubmed/35754026
http://dx.doi.org/10.1186/s13046-022-02416-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235180/
https://www.ncbi.nlm.nih.gov/pubmed/35754026
http://dx.doi.org/10.1186/s13046-022-02416-z

Ejemplares similares